Addex Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Addex Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Addex Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Addex Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Addex Therapeutics Ltd (Addex) is a clinical-stage pharmaceutical company primarily engaged in the development of novel orally available small molecule drug candidates. The company's portfolio includes a pipeline of proprietary clinical and preclinical stage drug candidates, developed both internally and in collaboration with partners. Addex's lead drug candidates include ADX71149, developed in partnership with Janssen Pharmaceuticals for the treatment of epilepsy, and dipraglurant, a wholly owned drug candidate under evaluation for Parkinson’s disease levodopa induced dyskinesia (PD-LID) and post-stroke/TBI recovery. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. The company's drug candidates are designed to address epilepsy, Parkinson’s disease, post-stroke sensorimotor recovery, traumatic brain injury, substance use disorder, and cough. Addex's products are primarily targeted towards the healthcare and pharmaceutical industries. The company collaborates with various partners, including Janssen Pharmaceuticals and Indivior PLC, for the development and commercialization of its drug candidates. Addex is headquartered in Geneva, Switzerland.
Headquarters
Switzerland
Address
Chemin Des Mines, 9, Geneva, 1202
Website
www.addextherapeutics.com/en
Telephone
41 22 8841555
No of Employees
3
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ADXN (SWF)
Revenue (2024)
$208,100
-57.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-195.4%
(2024 vs 2023)
Market Cap*
$10.8M
Net Profit Margin (2024)
XYZ
-326.2%
(2024 vs 2023)
* As of and is in US$
Addex Therapeutics Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Dipraglurant-IR: for PD- Levodopa Induced Dyskinesia |
| ADX71149: Epilepsy |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In April, the company entered into an agreement with Sinntaxis AB, for an exclusive license to intellectual property covering the use of mglu5 inhibitors in brain injury recovery. |
| 2024 | Others | In April, the company along with Perceptive Advisors launched Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders. |
| 2023 | Others | In September, the company received EUR4 million Eurostars grant to support its metabotropic glutamate 2 (mGlu2) receptor negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD). |
Competitor Comparison
| Key Parameters | Addex Therapeutics Ltd | Eli Lilly and Co | Merck & Co Inc | AstraZeneca Plc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | United Kingdom | Switzerland |
| City | Geneva | Indianapolis | Rahway | Cambridge | Basel |
| State/Province | - | Indiana | New Jersey | Cambridgeshire | Basel-Stadt |
| No. of Employees | 3 | 50,605 | 75,000 | 96,100 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vincent Lawton | Chairman | Executive Board | 2009 | 77 |
| Tim Dyer | Chief Executive Officer; Director | Executive Board | 2013 | 58 |
| Roger G. Mills, M.D. | Chief Medical Officer; Director | Executive Board | 2017 | 69 |
| Mikhail Kalinichev, PhD | Head - Translational Science | Senior Management | 2021 | 59 |
| Lenaic Teyssedou | Head - Finance | Senior Management | 2024 | 41 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer